DYN · Dyne Therapeutics, Inc.
$15.47
+0.03 (+0.19%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$2.91B
Shares
186.75M
Volume · Oct 5
4.38M
Avg daily vol (3M)
2.75M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.44
Open$15.31
Day$15.08–15.54
52W close$12.65–26.78
Avg vol 30d3.2M
Short int23.4M · 12.5% float · 5.5d
Short vol54%
Last earningsSep 3, 2024
DataSep 2020–Oct 2026
Filing10-Q · Jul 29
Up next
filed Jul 29, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$519.41M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-16.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$476.79M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.9%
Year over year · more shares
Price change (1Y)
+21.1%
Trailing year
Short interest
12.5%
Latest settlement · 5.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
−31%
below
RSI (14)
24
oversold
MACD trend
Positive
52-week position
20%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−36%
trailing
6-month return
−22%
trailing
YTD return
−21%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $22 › 200d $20 — 50d above 200d
Institutional flow
Flat
2 of 246 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.52% of float · ▲ +12.5% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
246 holders — near 3-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
EPS growth
−3%
Y/Y
Free cash flow
$-405.1M
Balance sheet
$744.4M
net cash
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−43%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
−31%
Bearish
RSI (14)
24
Neutral
MACD trend
Positive
Bullish
52-week position
20%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $22 › 200d $20 — 50d above 200d
Institutional flow
Flat
2 of 246 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.52% of float · ▲ +12.5% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
246 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13
Now $15 · 20%
Range high $27
vs 200-day avg -21%
vs 50-day avg -31%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DYN
this stock
Dyne Therapeutics, Inc.
|
$2.91B | -21.1% | — | — | 12.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DYN | -5.5% | -36.4% | -22.1% | -4.2% | -21.1% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -6.7% | -37.0% | -33.6% | -5.8% | -34.7% |